To include your compound in the COVID-19 Resource Center, submit it here.

CGT003 E2F Decoy: Phase III

Corgentech completed enrollment of 1,400 patients in PREVENT 3,

Read the full 97 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE